Statistics

Total Visits

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)40

Select a period of time:

Number of views in the range

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)13

Views

Views
November 20250
December 20252
January 20260
February 20260
March 20260
April 20260
May 202611
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
Angola1
China1
Germany1
France1
United Kingdom1
 

Top cities views

Views
Bismarck1
Frankfurt am Main1
London1
Miami1